Regulatory Approval

Aligos Therapeutics secures a key partnership and regulatory fast-track in China, signaling a major financial and clinical validation for its novel HBV drug.

With its first FDA clearance, Movmedix introduces a synthetic ligament used in 250,000+ global procedures. But can it win over a U.S. market wary of its history?

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

After a Health Canada-mandated pause, LSL's Steri-Med is near full remediation. This is more than a fix—it’s a calculated play for North American market leadership.

Cerezen, a non-invasive device shown to reverse cognitive decline, has EU approval but remains in FDA limbo, raising questions about US patient access.

Circus SE's autonomous kitchens are coming to UAE high-rises. It's a bold leap for urban food security, but can robotic sustenance truly feed a city?

After a successful FIFA World Cup debut, ADI Predictstreet is expanding. We explore how Gibraltar's regulatory gambit and blockchain tech are creating a new global forecasting tool.

YD Bio is expanding its U.S. lab network, but the real story is its strategy: turning diagnostic tests into a vast data engine to power the future of cancer research.

After a legal challenge, Peter Ballantyne Cree Nation now backs Denison's flagship project, de-risking a major future source of global uranium supply.

With a federal green light, the Springpole mine promises jobs and gold, but its real test lies in meeting strict environmental and Indigenous partnership terms.

Advicenne's unlimited UK drug approval for Sibnayal® is a win for rare disease patients, but it's one piece in a high-stakes global strategy now targeting the US market.

After completing massive studies, the Utah firm is readying an FDA submission that could move gold-standard diagnostics from the lab to your local clinic.

STARMED secures a landmark FDA clearance for its thyroid RFA system, the first of its kind, promising a minimally invasive alternative to surgery.

With its acquisition of French startup QPerfect, BTQ isn't just buying software; it's buying a strategic R&D hub and a powerful emulation-first approach.

Oklo's Texas reactor just cleared a major safety hurdle. It's more than a win for one company; it's a test of a new, faster model for U.S. nuclear deployment.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

A small NJ town sells its water system for $6.4M to tackle aging pipes and PFAS. What does this mean for residents and the future of public utilities?